Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Around 7% of the Indian population suffers from IBS
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
